Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.
复制标题
DOI：
10.5402/2011/645641
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Carr A
中科院分区：
文献类型：
--
作者：
Blanco R;Rengifo E;Cedeño M;Rengifo CE;Alonso DF;Carr A
先前已报告N-乙醇酰GM 3（NeuGcGM 3）神经节苷脂在人正常组织中的有限表达，以及使用14 F7 Mab（抗NeuGcGM 3）在黑色素瘤和乳腺癌中的存在。本研究首次评价了14 F7单抗在消化系统肿瘤中的免疫识别作用。用14 F7进行免疫组织化学测定，然后用抗小鼠生物素化抗体和ABC/HRP系统在正常和病理人体组织中进行。在正常组织中未发现免疫反应。14 F7的反应性在所有胃腺癌（12/12）、结肠癌（12/12）和胰腺癌（11/11）中检测到。在食管癌（5/15）、直肠表皮样癌（5/7）、直肠基底细胞样癌（4/5）和肝细胞癌（13/14）中也观察到细颗粒免疫识别。我们的结果与以下假设一致：NeuGcGM 3神经节苷脂可被视为表达该分子的消化系统恶性肿瘤的被动和主动免疫治疗的靶点。
The limited expression of N-Glycolyl GM3 (NeuGcGM3) ganglioside in human normal tissues, as well as its presence in melanoma and breast carcinoma using 14F7 Mab (anti-NeuGcGM3), has been previously reported. In this work we evaluated for the first time the 14F7 Mab immunorecognition in some digestive system tumors. Immunohistochemical assays were made with 14F7, followed by anti-mouse biotinylated antibody and ABC/HRP system in normal and pathological human tissues were made. No immunoreaction was evidenced in normal tissues. The reactivity of 14F7 was detected in all adenocarcinomas of the stomach (12/12), colon (12/12), and pancreas (11/11). A finely granular immunorecognition in esophageal tumors (5/15), epidermoid carcinoma of the rectum (5/7), and basaloid carcinoma (4/5) of the latter as well as in hepatocellular carcinoma (13/14) was also observed. Our results are in agreement with the assumption that NeuGcGM3 ganglioside may be considered as target for passive and active immunotherapy in digestive system malignancies expressing this molecule.